Skip to main content

Emerging therapeutics for myasthenia gravis

Publication ,  Conference
Punga, AR; Kaminski, HJ; Guptill, JT
Published in: Current Clinical Neurology
January 1, 2018

At no time in the history of myasthenia gravis has there been a time of greater therapeutic development. This situation likely stems from the well-defined pathophysiology of MG, which has made target identification relatively straightforward for drug development in the pharmaceutical industry and academic laboratories. Financial incentives to develop therapies for rare diseases have also been a positive factor. The present review assesses conventional treatments and drugs in preclinical and clinical trials

Duke Scholars

Published In

Current Clinical Neurology

DOI

EISSN

2524-4043

ISSN

1559-0585

Publication Date

January 1, 2018

Volume

0

Start / End Page

319 / 333
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Punga, A. R., Kaminski, H. J., & Guptill, J. T. (2018). Emerging therapeutics for myasthenia gravis. In Current Clinical Neurology (Vol. 0, pp. 319–333). https://doi.org/10.1007/978-3-319-73585-6_20
Punga, A. R., H. J. Kaminski, and J. T. Guptill. “Emerging therapeutics for myasthenia gravis.” In Current Clinical Neurology, 0:319–33, 2018. https://doi.org/10.1007/978-3-319-73585-6_20.
Punga AR, Kaminski HJ, Guptill JT. Emerging therapeutics for myasthenia gravis. In: Current Clinical Neurology. 2018. p. 319–33.
Punga, A. R., et al. “Emerging therapeutics for myasthenia gravis.” Current Clinical Neurology, vol. 0, 2018, pp. 319–33. Scopus, doi:10.1007/978-3-319-73585-6_20.
Punga AR, Kaminski HJ, Guptill JT. Emerging therapeutics for myasthenia gravis. Current Clinical Neurology. 2018. p. 319–333.

Published In

Current Clinical Neurology

DOI

EISSN

2524-4043

ISSN

1559-0585

Publication Date

January 1, 2018

Volume

0

Start / End Page

319 / 333